-
Acute Lymphoblastic Leukaemia Review | Assay Genie(Post)
Incidence rate of Acute Lymphoblastic Leukaemia Acute lymphoblastic leukaemia (ALL) is one of the most common malignant diseases diagnosed in children. It
Spotlight on Mitochondria(Post)Throughout my graduate and postgraduate studies I have been really intrigued and fascinated by the mitochondria, the organelle that keeps all of us running everyday! The more I learn about
COVID-19 Rapid POC CE-IVDテスト(25テスト)| Assay Genie(Post)COVID-19 Rapid POC CE-IVDテスト(25テスト) 概要説明 Getein COVID-19 Rapid POC(臨床現場即時)キットは新型コロナウィルス(
Loading Control Antibodies(Page)Loading Control Antibodies | GAPDH, \u03b2-Actin & Tubulin | Assay Genie
A Comprehensive Overview of Cell Death(Post)Cell death is an essential aspect of cellular biology that plays a crucial role in development, homeostasis, and disease. In this blog, we try to focus on mechanisms and various type
Utomilumab: Advancing Immuno-Oncology Research(Post)Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
The Complement System - pathways & function in the immune system(Post)The Complement System Function Gone are the days when the complement system was considered solely a companion of its impressive adaptive immune system counte
Metabolic Exhaustion: How Mitochondrial Dysfunction Sabotages CAR-T Cell Therapy in Solid Tumors(Post)Imagine engineering a patient's own immune cells into precision-guided missiles against cancer—cells that can seek out and destroy tumors with remarkable specificity. This is the promise of CAR-T cell
COVID-19(SARS-CoV-2)トリプレックスRT-qPCR検出キット| Assay Genie(Post)COVID-19(SARS-CoV-2)トリプレックスRT-qPCR検出キット COVID-19アッセイの概要: この製品は、新規コロナウイルスSARS-CoV-2によって引き
PCR Detection of COVID-19 (SARS-CoV-2)(Post)PCR Detection of COVID-19 (SARS-CoV-2) Contents Background Assay Information Sample Types Upp
Understanding activating PIK3CA mutations in human disease(Post)Ralitsa R. Madsen – University of Cambridge Metabolic Research Laboratories Each one of us is the result of an extraordinary developmental proces
Pinatuzumab: Advancing Cancer Research and Therapeutics(Post)Quick Facts About PinatuzumabWhat is Pinatuzumab?Pinatuzumab is an antibody-drug conjugate (ADC) designed to target CD22, a protein highly expressed on B-cell malignancies, including non
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like
Immunohistochemical Staining, Antibodies & Buffers(Page) Hemocytometer Cell Counting Procedure(Post)Cell Culture · ProtocolsHaemocytometer Cell Counting: Procedure, Calculation and Common ErrorsA haemocytometer turns a known chamber volume into a cell concentration, and the whole method rests on fou
43 Science Instagrams You Need To Follow: The Instagram Influencer-Ome(Post)Social media has become a powerful tool for science communication, and Instagram is no exception. The platform is home to a diverse array of science influencers, ranging from PhD students to estab
QuickStep ELISA Kits(Page)QuickStep ELISA Kits | 90-Minute 1-Wash Assays | Assay Genie
What are MHC Class I and II molecules?(Post)What are MHC Class I molecules? The MHC class I is a glycoprotein that is expressed on all nucleated cells of the human body. MHC class I are important in disease defense against viruses, ba
Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics(Post)Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the me
Indusatumab: Advancing Anti-CD47 Cancer Research with Biosimilar Innovations(Post)Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does